Recall processes for biliary cytology in primary sclerosing cholangitis

Current Opinion in Gastroenterology

Volumn 30, Issue 3, 2014, Pages 287-294

  Eaton, John E ^a   Gossard, Andrea A ^a   Talwalkar, Jayant A ^a  

^a MAYO CLINIC   (United States)

Author keywords

biliary cytology; cholangiocarcinoma; fluorescence in situ hybridization; primary sclerosing cholangitis

Indexed keywords

CA 19-9 ANTIGEN;

BILE DUCT CARCINOMA; BILIARY CYTOLOGY; CANCER DIAGNOSIS; CYTOLOGY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FLUORESCENCE IN SITU HYBRIDIZATION; HEPATOBILIARY SYSTEM; HUMAN; PERCUTANEOUS TRANSHEPATIC CHOLANGIOGRAPHY; PREDICTION; PRIMARY SCLEROSING CHOLANGITIS; PROTEOMICS; REVIEW; RISK; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; COMPLICATION; CYTODIAGNOSIS; EARLY DIAGNOSIS; INTRAHEPATIC BILE DUCT; PROCEDURES; SCLEROSING CHOLANGITIS;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; CHOLANGITIS, SCLEROSING; CYTODIAGNOSIS; EARLY DETECTION OF CANCER; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE;

EID: 84898541693     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000055     Document Type: Review

References (25)

1. Eaton JE, Talwalkar JA, Lazaridis KN, et al. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology 2013; 145:521-536.
2. Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002; 36:321-327.
3. Sirica AE. Cholangiocarcinoma: molecular targeting strategies for chemo-prevention and therapy. Hepatology 2005; 41:5-15.
4. Razumilava N, Gores GJ, Lindor KD. Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology 2011; 54:1842-1852.
5. Darwish Murad S, Kim WR, Harnois DM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocar-cinoma at 12 US centers. Gastroenterology 2012; 143:88-98.
6. Barr Fritcher EG, Voss JS, Jenkins SM, et al. Primary sclerosing cholangitis with equivocal cytology: Fluorescence in situ hybridization and serum CA 19-9 predict risk of malignancy. Cancer Cytopathol 2013; 121:708-717.
7. Moreno Luna LE, Kipp B, Halling KC, et al. Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology 2006; 131:1064-1072.
8. Trikudanathan G, Navaneethan U, Njei B, et al. Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointest Endosc 2013. [Epub ahead of print]
9. Harewood GC, Baron TH, Stadheim LM, et al. Prospective, blinded assess ment of factors influencing the accuracy of biliary cytology interpretation. Am J Gastroenterol 2004; 99:1464-1469.
10. Alkhatib AA, Hilden K, Adler DG. Comorbidities, sphincterotomy, and balloon dilation predict post-ERCP adverse events in PSC patients: operator experience is protective. Dig Dis Sci 2011; 56:3685-3688.
11. Ismail S, Kylanpaa L, Mustonen H, et al. Risk factors for complications of ERCP in primary sclerosing cholangitis. Endoscopy 2012; 44:1133-1138.
12. Kipp BR, Barr Fritcher EG, Pettengill JE, et al. Improving the accuracy of pancreatobiliary tract cytology with fluorescence in situ hybridization: a molecular test with proven clinical success. Cancer Cytopathol 2013; 121:610-609.
13. Bergquist A, Tribukait B, Glaumann H, et al. Can DNA cytometry be used for evaluation of malignancy and premalignancy in bile duct strictures in primary sclerosing cholangitis? J Hepatol 2000; 33:873-877.
14. Bangarulingam SY, Bjornsson E, Enders F, et al. Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholan-gitis. Hepatology 2010; 51:174-180.
15. Barr Fritcher EG, Kipp BR, Voss JS, et al. Primary sclerosing cholangitis patients with serial polysomy fluorescence in situ hybridization results are at increased risk of cholangiocarcinoma. Am J Gastroenterol 2011; 106:2023-2028.
16. Levy C, Lymp J, Angulo P, et al the value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci 2005; 50:1734-1740.
17. Charatcharoenwitthaya P, Enders FB, Halling KC, et al. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 2008; 48:1106-1117.
18. Sinakos E, Saenger AK, Keach J, et al. Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma. Clin Gastroenterol Hepatol 2011; 9:434-439.
19. Venkatesh PG, Navaneethan U, Shen B, et al. Increased serum levels of carbohydrate antigen 19-9 and outcomes in primary sclerosing cholangitis patients without cholangiocarcinoma. Dig Dis Sci 2013; 58:850-857.
20. Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51:660-678.
21. Metzger J, Negm AA, Plentz RR, et al. Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Gut 2013; 62:122-130.
22. Lankisch TO, Metzger J, Negm AA, et al. Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocho-lithiasis. Hepatology 2011; 53:875-884.
23. Sandanayake NS, Sinclair J, Andreola F, et al. A combination of serum leucine-rich alpha-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures. Br J Cancer 2011; 105:1370-1378.
24. Kipp BR, Fritcher EG, Clayton AC, et al. Comparison of KRAS mutation analysis and FISH for detecting pancreatobiliary tract cancer in cytology specimens collected during endoscopic retrograde cholangiopancreatogra-phy. J Mol Diagn 2010; 12:780-786.
25. Ahlquist DA, Zou H, Domanico M, et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology 2012; 142:248-256.